Medis offers a broad portfolio of products to pharmaceutical companies. We currently provide more than 170 pharmaceutical products for human use, mainly in the form of tablets, capsules and injections.The R&D specialists we collaborate with at Actavis maintain a strong development pipeline, enabling the timely availability of new products for our customers.

Medis has also established itself as a reliable source of pharmaceutical intellectual property in the form of comprehensive registration dossiers. We have a solid track record of securing regulatory approval prior to patent expiries. Our vast experience in launching new products and our proven regulatory skills contribute to a highly successful approach, which gets results fast. Medis has obtained marketing authorisations in over 50 countries to date and exports to most European nations, as well as other regions of the world.

Oncology products

Now featured in our comprehensive portfolio is a growing range of specialist oncology products. The current oncology portfolio consists of over 15 available dossiers. Many more dossiers are expected to be completed over the next few years. 

In 2007, Medis established a number of partnerships with pharmaceutical companies dedicated to the hospital market.  So, if your current or future business strategy includes a focus on hospital markets and oncology products, please feel free to contact us for further information and advice.

For more information on all available products and dossiers, and our development pipeline please email medis@medis.is